{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:24:27Z","timestamp":1780619067639,"version":"3.54.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>We aimed to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the impact of a polypill-based strategy (PBS) on therapeutic adherence and cardiovascular outcomes compared with usual care for secondary prevention of cardiovascular diseases (CVDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We systematically searched PubMed, Cochrane, and Scopus databases from inception to January 2023, including RCTs comparing PBS with usual care in patients with prior CVD. We assessed efficacy outcomes of therapeutic adherence, systolic blood pressure (SBP), and LDL-cholesterol (LDL-C) and safety outcomes of all-cause and cardiovascular mortality. Statistical analysis was performed with Review Manager 5.4.1 and R Version 4.2.1. A total of 8 RCTs with a population of 6541 individuals were included, of whom 3318 (50.7%) were treated with the PBS. Follow-up ranged from 6 to 60 months. The polypill-based strategy was associated with a significantly increased therapeutic adherence [risk ratio (RR) 1.22; 95% confidence interval (CI) 1.10\u20131.34; P &amp;lt; 0.001]. Cardiovascular mortality (RR 0.61; 95% CI 0.44\u20130.85; P = 0.004), SBP [mean difference (MD) \u22121.47 mmHg; 95% CI \u22122.86 to \u22120.09; P = 0.04], and LDL-C (MD \u22123.83 mg\/dL; 95% CI \u22126.99 to \u22120.67; P = 0.02) were significantly lower in the PBS group. The incidence of all-cause mortality was similar between groups (RR 0.83; 95% CI 0.54\u20131.29; P = 0.41).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with pre-existing CVD, a PBS is associated with lower cardiovascular mortality and improved therapeutic adherence, along with a modest decrease in SBP and LDL-C compared with usual care. Thus, a PBS may be considered a preferred option for this patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwad245","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T21:58:37Z","timestamp":1690322317000},"page":"1828-1837","source":"Crossref","is-referenced-by-count":16,"title":["Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1310-1590","authenticated-orcid":false,"given":"Andr\u00e9","family":"Rivera","sequence":"first","affiliation":[{"name":"Department of Medicine, Nove de Julho University , S\u00e3o Bernardo do Campo , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8359-6789","authenticated-orcid":false,"given":"Bruno","family":"Campos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Maur\u00edcio de Nassau University , Cacoal , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-5918","authenticated-orcid":false,"given":"Stephanie","family":"Ceolin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vila Velha University , Vila Velha , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-7786","authenticated-orcid":false,"given":"Amanda","family":"Godoi","sequence":"additional","affiliation":[{"name":"School of Medicine, Cardiff University , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-7849","authenticated-orcid":false,"given":"Everton","family":"Castanha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Federal University of Pelotas, Pelotas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5290-7294","authenticated-orcid":false,"given":"Carlos Alberto","family":"Campello Jorge","sequence":"additional","affiliation":[{"name":"Department of Medicine, Federal University of Mato Grosso , Cuiab\u00e1 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-7605","authenticated-orcid":false,"given":"Rhanderson","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Harvard Medical School, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"2023111020351827700_zwad245-B1","doi-asserted-by":"crossref","first-page":"e005375","DOI":"10.1161\/CIRCOUTCOMES.118.005375","article-title":"Mortality from ischemic heart disease: analysis of data from the World Health Organization and coronary artery disease risk factors from NCD risk factor collaboration","volume":"12","author":"Nowbar","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2023111020351827700_zwad245-B2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0140-6736(17)32471-6","article-title":"Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition","volume":"391","author":"Prabhakaran","year":"2018","journal-title":"Lancet"},{"key":"2023111020351827700_zwad245-B3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"2023111020351827700_zwad245-B4","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"2023111020351827700_zwad245-B5","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/archinte.1993.00410160029002","article-title":"Recall of recommendations and adherence to advice among patients with chronic medical conditions","volume":"153","author":"Kravitz","year":"1993","journal-title":"Arch Intern Med"},{"key":"2023111020351827700_zwad245-B6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/CIRCULATIONAHA.109.904003","article-title":"Medication adherence in cardiovascular disease","volume":"121","author":"Baroletti","year":"2010","journal-title":"Circulation"},{"key":"2023111020351827700_zwad245-B7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"2023111020351827700_zwad245-B8","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","article-title":"Blood-pressure and cholesterol lowering in persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"2023111020351827700_zwad245-B9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N Engl J Med"},{"key":"2023111020351827700_zwad245-B10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","article-title":"Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial","volume":"373","author":"Yusuf","year":"2009","journal-title":"Lancet"},{"key":"2023111020351827700_zwad245-B11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2022.04.085","article-title":"Polypill for cardiovascular disease prevention: systematic review and meta-analysis of randomized controlled trials","volume":"360","author":"Mohamed","year":"2022","journal-title":"Int J Cardiol"},{"key":"2023111020351827700_zwad245-B12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pcad.2022.01.005","article-title":"Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Rao","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"2023111020351827700_zwad245-B13","first-page":"e34134","article-title":"Effect of the polypill on adherence and prevention of cardiovascular diseases in patients with or at high risk of cardiovascular diseases: a meta-analysis of randomized controlled trials","volume":"15","author":"Memon","year":"2023","journal-title":"Cureus"},{"key":"2023111020351827700_zwad245-B14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amepre.2022.03.027","article-title":"Fixed-dose combination (polypill) for cardiovascular disease prevention: a meta-analysis","volume":"63","author":"Abushouk","year":"2022","journal-title":"Am J Prev Med"},{"key":"2023111020351827700_zwad245-B15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"2023111020351827700_zwad245-B16","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/eurheartj\/ehab919","article-title":"Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial","volume":"43","author":"Merat","year":"2022","journal-title":"Eur Heart J"},{"key":"2023111020351827700_zwad245-B17","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed."},{"key":"2023111020351827700_zwad245-B18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Chichester","author":"Higgins","year":"2019"},{"key":"2023111020351827700_zwad245-B19","author":"Sch\u00fcnemann"},{"key":"2023111020351827700_zwad245-B20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023111020351827700_zwad245-B21","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1177\/0962280219889080","article-title":"Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis","volume":"29","author":"McGrath","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"2023111020351827700_zwad245-B22","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023111020351827700_zwad245-B23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2023111020351827700_zwad245-B24","doi-asserted-by":"crossref","first-page":"g3318","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"key":"2023111020351827700_zwad245-B25","doi-asserted-by":"crossref","DOI":"10.1177\/1753944720912071","article-title":"Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial","volume":"14","author":"Mariani","year":"2020","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2023111020351827700_zwad245-B26","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA"},{"key":"2023111020351827700_zwad245-B27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","article-title":"Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial","volume":"394","author":"Roshandel","year":"2019","journal-title":"Lancet"},{"key":"2023111020351827700_zwad245-B28","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"2023111020351827700_zwad245-B29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1755-5922.12151","article-title":"The effect of a cardiovascular polypill strategy on pill burden","volume":"33","author":"Truelove","year":"2015","journal-title":"Cardiovasc Ther"},{"key":"2023111020351827700_zwad245-B30","doi-asserted-by":"crossref","first-page":"e0271908","DOI":"10.1371\/journal.pone.0271908","article-title":"Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: a systematic literature review","volume":"17","author":"Jahangiri","year":"2022","journal-title":"PLoS One"},{"key":"2023111020351827700_zwad245-B31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.082","article-title":"Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: within-trial cost-effectiveness analysis of the UMPIRE trial","volume":"262","author":"Singh","year":"2018","journal-title":"Int J Cardiol"},{"key":"2023111020351827700_zwad245-B32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"2023111020351827700_zwad245-B33","doi-asserted-by":"crossref","first-page":"21A","DOI":"10.1016\/j.amjcard.2009.10.010","article-title":"Are there effects of renin\u2013angiotensin system antagonists beyond blood pressure control?","volume":"105","author":"Bakris","year":"2010","journal-title":"Am J Cardiol"},{"key":"2023111020351827700_zwad245-B34","author":"World Health Organization (WHO)"},{"key":"2023111020351827700_zwad245-B35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwad245\/51102045\/zwad245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/30\/16\/1828\/53049426\/zwad245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/30\/16\/1828\/53049426\/zwad245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T20:35:48Z","timestamp":1699648548000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/30\/16\/1828\/7231039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":35,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,7,25]]},"published-print":{"date-parts":[[2023,11,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwad245","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,7,25]]}}}